What is the official website of Synoptis Pharma ?

The official website of Synoptis Pharma is http://synoptispharma.pl.

What is Synoptis Pharma's cybersecurity risk score?

Synoptis Pharma has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Synoptis Pharma experienced?

According to Rankiteo, Synoptis Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Synoptis Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, Synoptis Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Synoptis Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, Synoptis Pharma is not certified under SOC 2 Type 1.

Does Synoptis Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, Synoptis Pharma does not hold a SOC 2 Type 2 certification.

Does Synoptis Pharma comply with GDPR ?

According to Rankiteo, Synoptis Pharma is not listed as GDPR compliant.

Does Synoptis Pharma have PCI DSS certification ?

According to Rankiteo, Synoptis Pharma does not currently maintain PCI DSS compliance.

Does Synoptis Pharma comply with HIPAA ?

According to Rankiteo, Synoptis Pharma is not compliant with HIPAA regulations.

Does Synoptis Pharma have ISO 27001 certification ?

According to Rankiteo,Synoptis Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Synoptis Pharma operate in ?

Synoptis Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Synoptis Pharma have ?

Synoptis Pharma employs approximately 86 people worldwide.

Does Synoptis Pharma own any subsidiaries ?

Synoptis Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does Synoptis Pharma have ?

Synoptis Pharma's official LinkedIn profile has approximately 2,165 followers.

What is the NAICS classification code for Synoptis Pharma ?

Synoptis Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Synoptis Pharma have a Crunchbase profile ?

No, Synoptis Pharma does not have a profile on Crunchbase.

Does Synoptis Pharma have a LinkedIn profile ?

Yes, Synoptis Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/synoptis-pharma.

How many cybersecurity incidents has Synoptis Pharma experienced ?

As of October 22, 2026, Rankiteo reports that Synoptis Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does Synoptis Pharma have ?

Synoptis Pharma has an estimated 5,782 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Synoptis Pharma

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Synoptis Pharma Vendor Cyber Rating & Cyber Score

synoptispharma.pl

Add Your Compliance Badge

Jesteśmy doświadczonym polskim producentem leków na receptę, OTC, suplementów diety, produktów kosmetycznych oraz dystrybutorem wyrobów medycznych. Należymy do Grupy NEUCA - lidera rynku około zdrowotnego. Naszą misją jest oferowanie produktów godnych zaufania, niosących za sobą wartość dla zdrowia i dobrostanu. Wykorzystując technologie, naukowe podejście oraz badania, tworzymy rozwiązania spełniające oczekiwania podmiotów rynku farmaceutycznego. Priorytetem zawsze jest jakość.

Synoptis Pharma

Synoptis Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Synoptis Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Synoptis Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Synoptis Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Synoptis Pharma in 2026.

Incident Types Synoptis Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Synoptis Pharma in 2026.

Incident History - Synoptis Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Synoptis Pharma Subsidiaries

Synoptis Pharma

Pharmaceutical Manufacturing

Website: http://synoptispharma.pl

Company Size: 51-200 employees

Grupa NEUCAPharmaceutical Manufacturing

KapadiResearch Services

OncoBay Clinical (now Kapadi)Research Services

GLOBAL PHARMA CM S.A.Pharmaceutical Manufacturing

Synoptis Industrial | NEUCA GroupPharmaceutical Manufacturing

Clinscience (now Kapadi)Research Services

PratiaResearch

hyggioIT Services and IT Consulting

Apteline.plRetail

NEKK - agencja pharmamarketingowaAdvertising Services

Aptekarski.comMedia and Telecommunications

NEUkubatorWellness and Fitness Services

Humaneva GroupResearch Services

Farmada Transport Sp. z o.o.Transportation, Logistics, Supply Chain and Storage

Exom Group (now Kapadi)Pharmaceutical Manufacturing

Operator Medyczny Świat ZdrowiaHospitals and Health Care

Loading…

Synoptis Pharma Similar Companies

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Loading…

NEWS

Synoptis Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-113705

SUMMARY

A vulnerability was determined in a2aproject a2a-rs up to 0.4.3. This issue affects some unknown processing of the file a2a-server/src/error.rs. Executing a manipulation can lead to information exposure through error message. The attack can be executed remotely. This patch is called 713b943af94ab2d521d483b841618b97a2e78a4d. A patch should be applied to remediate this issue.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 5.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:N/A:N

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:N/A:N

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-9825

SUMMARY

IBM Cyber Fraud 1.0.0 through 1.0.2 has a missing secure attribute allowing sensitive cookies to be transmitted over unencrypted connections, potentially enabling an attacker to intercept session data through network-based attacks.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:L/I:N/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

https://www.ibm.com/support/pages/node/7290671

CVE-2026-94402

SUMMARY

IBM Carbon Charts 0.4.0 through 1.27.19 is vulnerable to cross-site scripting. The MeterChart component's Title.truncateTitle() function re-inserts a substring of user-supplied label text into the DOM via an unsanitized innerHTML write when the title exceeds the available container width. A remote attacker could exploit this vulnerability to execute arbitrary JavaScript in the victim's browser session.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 6.1)

cvss3

Base Score: 6.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Impact Score

2.7

Exploitability

2.8

REFERENCES

https://www.ibm.com/support/pages/node/7291785

CVE-2026-93888

SUMMARY

IBM Sterling Connect Direct for Unix 6.4.0.0 through 6.4.0.6 and 6.3.0.0 through 6.3.0.7 apnotify utility is vulnerable to a code injection due to insufficient validation of user input.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

1.8

REFERENCES

https://www.ibm.com/support/pages/node/7292127

CVE-2026-93744

SUMMARY

IBM i 7.3, 7.4, 7.5, and 7.6 could allow an unathenticated remote attacker to bypass security restrictions due to improper access control. By sending a specially crafted HTTP request to any URL within the Navigator application prior to authentication, a bad actor could exploit this vulnerability to alter server-side session security state.

Published

Date2026-10-20

Updated

Date2026-10-20

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

3.9

REFERENCES

https://www.ibm.com/support/pages/node/7292223

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Synoptis Pharma Vendor Cyber Rating & Cyber Score

Synoptis Pharma A.I CyberSecurity Scoring

Synoptis Pharma CyberSecurity News & History

Synoptis Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Synoptis Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Synoptis Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Synoptis Pharma (X = Date, Y = Severity)

Synoptis Pharma Subsidiaries

Synoptis Pharma

Synoptis Pharma Similar Companies

Alkem Laboratories Ltd.

AUROBINDO PHARMA LTD

Bristol Myers Squibb

MSD

Lonza

Astellas Pharma

Grifols

Novo Nordisk

AbbVie

Synoptis Pharma CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Synoptis Pharma CyberSecurity News & History

Synoptis Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Synoptis Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Synoptis Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Synoptis Pharma (X = Date, Y = Severity)

Synoptis Pharma Subsidiaries

Synoptis Pharma

Synoptis Pharma Similar Companies

Alkem Laboratories Ltd.

AUROBINDO PHARMA LTD

Bristol Myers Squibb

MSD

Lonza

Astellas Pharma

Grifols

Novo Nordisk

AbbVie

Synoptis Pharma CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo